

<b>National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines: COLORECTAL CANCER</b>	<b>Original Date: March 2011</b>
<b>Radiation Oncology</b>	<b>Last Revised Date: February 2020</b>
<b>Guideline Number: NIA_CG_121</b>	<b>Implementation Date: January 2021</b>

## INDICATIONS FOR RADIATION THERAPY

- **Colon Cancer**
  - Radiation Therapy is indicated for T4 tumors with penetration/perforation, intermediate/positive margins or for palliative care to relieve symptoms for Stage IV metastatic disease. Radiation therapy should not replace surgical resection.
    - 3D Conformal is recommended. 45-50 Gy in 25-28 fractions. Boost dose for positive margins an option (NCCN, 2018a).
    - IORT, if available, should be considered for very close or positive margins following resection, particularly for T4 or recurrent cancers, as an additional boost (NCCN, 2018a). Where IORT is not available, 10-20 Gy external beam radiation and/or brachytherapy to a limited volume can be considered soon after surgery but prior to adjuvant chemotherapy.
    - IMRT is not indicated as a standard treatment option and should be reserved for unique situations but may be utilized for re-irradiation of previously treated patients with recurrence (NCCN, 2018a). (Requires Physician Review)
  - Proton beam is not an approved treatment option for colorectal cancer.
- **Rectal Cancer**
  - Radiation therapy is considered a medically necessary for the following clinical indications: Preoperative or postoperative/adjuvant therapy or as primary therapy if tumor inoperable. Radiation therapy should not replace surgical resection (NCCN, 2018b).
    - 3D Conformal Radiation Therapy recommended. 45 -54 Gy delivered 25 -30 fractions at 1.8 -2.0 Gy per fraction. Boost may be an option. Dosage exceeding 54 Gy may be necessary for un-resectable tumors (NCCN, 2018b).

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- IORT, if available, should be considered for very close or positive margins following resection, particularly for T4 or recurrent cancers, as an additional boost. Where IORT is not available, 10-20 Gy external beam radiation and/or brachytherapy to a limited volume can be considered soon after surgery but prior to adjuvant chemotherapy (NCCN, 2018b).
- IMRT is not indicated as a standard treatment option and should be reserved for unique situations but may be utilized for re-irradiation of previously treated patients with recurrence (NCCN, 2018b). (Requires Physician review)
- Proton beam is not an approved treatment option for colorectal cancer.

#### **TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW:**

##### **Intensity Modulated Radiation Therapy (IMRT)**

IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for colorectal cancer. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created.

Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:

- Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of a patient specific dose volume histograms and isodose plans.
- Provide tissue constraints for both the target and affected critical structures.

##### **Proton Beam Radiation Therapy**

Proton beam is not an approved treatment option for colorectal cancer. There are limited clinical studies comparing proton beam therapy to 3-D conformal radiation. Overall, studies have not shown clinical outcomes to be superior to conventional radiation therapy.

#### **THE FOLLOWING APPLIES TO CMS (MEDICARE) MEMBERS ONLY:**

*For Proton Beam and Stereotactic Radiotherapy refer to Local Coverage Determination (LCD), if applicable*

---

**BACKGROUND:**

Colorectal cancer, also called colon cancer or large bowel cancer includes cancerous growths in the colon, rectum and appendix. Cancer of the colon is generally treated with both surgery and chemotherapy. Surgery may be used in the treatment of all stages of rectal cancer. Preoperative radiation therapy and chemotherapy (neoadjuvant therapy) are given to shrink the tumor before surgery, resulting in improved probability for successful resection. Postoperative radiation therapy and chemotherapy (adjuvant therapy) may decrease local recurrence and improve overall survival. It may also be used for palliative treatment to relieve symptoms of metastatic disease. In addition, local recurrences that cause pain, bleeding or other symptoms are appropriately treated with radiation therapy.

**POLICY HISTORY:**

**Review Date:** February 2019

**Review Summary:**

- Removed section: 'Pediatric Considerations' for consistency with other GLs
- Added and updated references

**Review Date:** February 2020

**Review Summary:** No changes

## REFERENCES:

Arbea L, Ramos LI, Martinez-Monge R, et al. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): Dosimetric comparison and clinical implications. *Radiat Oncol*. February 26, 2010; 5:17.

Goodman KA, Patton CE, Fisher GA, et al. Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. <http://www.practicalradonc.org/cms/attachment/2054445147/2060721817/mmc1.pdf>. Accessed May 12, 2017.

Hong TS, Moughan J, Garofalo MC, et al. NRG Oncology Radiation Therapy Oncology Group 0822: A phase II study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with Capecitabine and Oxaliplatin for patients with locally advanced rectal cancer. [Published online ahead of print May 14, 2015]. *Int J Radiat Oncol Biol Phys*. September 1, 2015; 93(1):29-36. doi: 10.1016/j.ijrobp.2015.05.005.

Meyer JJ, Willett CG, Czito BG. Emerging role of intensity-modulated radiation therapy in anorectal cancer. *Expert Rev Anticancer Ther*. April 2008; 8(4):585-593.

Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. [Published online ahead of print December 29, 2008]. *Int J Radiat Oncol Biol Phys*. July 1, 2009; 74(3):824-830.

National Cancer Institute (NCI). Colon Cancer. 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Published March 14, 2018. Accessed April 24, 2018.

National Comprehensive Cancer Network (NCCN). Colon Cancer. 4.2018a. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed February 7, 2019.

National Comprehensive Cancer Network (NCCN). Rectal Cancer. 1.2018b. [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). March 14, 2018. Accessed April 24, 2018.

Reviewed / Approved by  Sri Gorty, M.D., Physician Clinical Reviewer, Radiation Oncology

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.